Strategies To Overcome and Prevent (STOP) Obesity Alliance


 

Driving innovative & Practical strategies to combat obesity

The Strategies to Overcome and Prevent (STOP) Obesity Alliance comprises a diverse group of individual, government, advocacy, business, and health organizations dedicated to reversing the obesity epidemic in the United States. Drawing on the strengths of the collaborative, the Alliance conducts research, makes policy recommendations, and develops hands-on tools for providers, advocates, consumers, and policymakers.

 


 

What we do to STOP obesity

Conduct Research

Analyze and publish data related to coverage and the costs of obesity, including direct medical and employer-borne costs, but also those related to stigma and bias that impact quality of care.

Develop Tools

Develop research-based patient and health care provider guides to facilitate respectful, productive conversations around weight. Generate reports and guidance that provide essential obesity-related information for policymakers, legislators, and other decision-makers.

Drive Collaboration

Convene key experts for meetings and roundtables to explore and address specific focus areas and barriers to obesity prevention, care, treatment, and coverage, and execute on identified needs.


 

 

Sign up for our monthly Newsletter

Subscribe below to receive STOP's monthly email. Each month it is packed with insights from experts in obesity prevention and treatment, details on upcoming events, and exciting news from our member organizations!

E‑newsletter Sign‑up Form

 

 


 

Resources

 


 

Recent Letters from our Director, Dr. William H. Dietz

 

June 2025 Letter from the Director

Guest Letter: Metabolic Health Matters: Addressing Obesity and Advancing Solutions in Fatty Liver Disease

June 28, 2025

On the second Thursday in June, Global Fatty Liver Day brings overdue attention to one of the most widespread yet overlooked public health threats of our time: fatty liver disease.

May 2025 Letter from Director

Employer Insurance Coverage of Obesity Treatment

May 29, 2025

Limitations in access and coverage of obesity medications has paralleled the advances in the usage of GLP-1s.

April 2025 Letter from the Director

Guest Letter: Concerns About Compounded GLP-1 Medications

April 29, 2025

OAC has long advised our members against using compounded GLP-1’s. The main reason is FDA’s own words about compounding.

 

 Explore the Director Letter Archive